Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711539 | 0.86 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL23682540 | 0.85 | OPRM1 (0.59) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL10598753 | 0.84 | OPRM1 (0.63) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL13561473 | 0.84 | P2RX7 (0.50) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL1303683 | 0.83 | DPP4 (0.53) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL10601133 | 0.83 | CYP1A2 (0.62) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL113896 | 0.83 | CYP1A2 (0.62) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL12513620 | 0.81 | MC4R (0.65) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL12508381 | 0.81 | KCNA5 (0.48) | OPRM1OPRD1OPRK1OPRL1KCNA5 | |
| SCHEMBL1667533 | 0.80 | ALDH1A1 (0.49) | KCNA5LMNAALDH1A1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365552-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | OPRM1 3986/4885OPRD1 4169/4885OPRK1 2836/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | OPRM1 11/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | OPRM1 11/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | OPRM1 11/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | OPRM1 11/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | OPRM1 2073/4885OPRD1 779/4885OPRK1 980/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | OPRM1 2073/4885OPRD1 779/4885OPRK1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.